Β-Arrestin2 influences the response to methadone in opioid-dependent patients

Pharmacogenomics Journal

Volumn 11, Issue 4, 2011, Pages 258-266

  Oneda, B ^a   Crettol, S ^a   Bochud, M ^b   Besson, J ^a   Croquette Krokar, M ^c,d   Hammig R ^e   Monnat, M ^a   Preisig, M ^a   Eap, C B ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d Fondation Phenix   (Switzerland)

^e Psychiatrische Universitatsklinik   (Switzerland)

Author keywords

ARRB2; methadone; SNP

Indexed keywords

BETA ARRESTIN 2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; METHADONE;

ADULT; AMINO ACID SEQUENCE; ARRB2 GENE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; ARRESTINS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; LOGISTIC MODELS; MALE; METHADONE; MIDDLE AGED; ODDS RATIO; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960618929     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.37     Document Type: Article

References (52)

1. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002; 23: 93-105. (Pubitemid 36151692)
2. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41: 1153-1193. (Pubitemid 35398691)
3. Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci 1995; 245: 114-124.
4. Ball JC, Ross A, Jaffe JH. Cocaine and heroin use by methadone maintenance patients. NIDA Res Monogr 1989; 95: 328. (Pubitemid 20347222)
5. Bament D, Cooke R, Weekly J, Ali R. Treatment outcomes at 12 months post admission to drug treatment: the third report of the South Australian component of the Australian Treatment Outcomes Study-Heroin. Adelaide: DASC Monograph No 16 Research Series 2004.
6. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78: 593-604. (Pubitemid 41773635)
7. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Hämmig R, Gothuey I et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80: 668-681. (Pubitemid 44920225)
8. Perez de los Cobos J, Siñol N, Trujols J, del Rio E, Banuls E, Luquero E et al. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007; 89: 190-194. (Pubitemid 46754669)
9. Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra GL, Deglon JJ et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007; 81: 719-728. (Pubitemid 46625109)
10. Crettol S, Digon P, Golay KP, Brawand M, Eap CB. In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology 2007; 80: 304-311. (Pubitemid 47557265)
11. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006; 80: 682-690. (Pubitemid 44920224)
12. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I et al. No influence of ABCB1 haplotypes on methadone dosage requirement-(Forum). Clin Pharmacol Ther 2008; 83: 668-669. (Pubitemid 351556009)
13. Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008; 17: 2219-2227. (Pubitemid 351916578)
14. Lawford BR, Young RM, Noble EP, Sargent J, Rowell J, Shadforth S et al. The D2 dopamine receptor A1 allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 2000; 96B: 592-598.
15. Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet 2006; 141B: 323-331. (Pubitemid 43872882)
16. Crettol S, Besson A, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1722-1727.
17. Connor M, Christie MD. Opioid receptor signalling mechanisms. Clin Exp Pharmacol Physiol 1999; 26: 493-499. (Pubitemid 29309619)
18. Satoh M, Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther 1995; 68: 343-364. (Pubitemid 26020722)
19. Lotsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmoller J et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006; 79: 72-89. (Pubitemid 43069580)
20. Comings DE, Gade R, Wu S, Chiu C, Dietz G, Muhleman D et al. Studies of the potential role of the dopamine d-1 receptor gene in addictive behaviors. Mol Psychiatry 1997; 2: 44-56. (Pubitemid 27163110)
21. Limosin F, Loze JY, Rouillon F, Ades J, Gorwood P. Association between dopamine receptor D1 gene DdeI polymorphism and sensation seeking in alcohol-dependent men. Alcohol Clin Exp Res 2003; 27: 1226-1228. (Pubitemid 36999210)
22. Kim DJ, Park BL, Yoon S, Lee HK, Joe KH, Cheon YH et al. 50 UTR polymorphism of dopamine receptor D1 (DRD1) associated with severity and temperament of alcoholism. Biochem Biophys Res Commun 2007; 357: 1135-1141. (Pubitemid 46722580)
23. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005; 57: 1-26. (Pubitemid 40283968)
24. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12: 205-216. (Pubitemid 36204418)
25. Doehring A, Hentig N, Graff J, Salamat S, Schmidt M, Geisslinger G et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 2009; 19: 407-414.
26. Hirvonen M, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 2004; 9: 1060-1061. (Pubitemid 40065447)
27. Cen B, Yu Q, Guo J, Wu Y, Ling K, Cheng Z et al. Direct binding of betaarrestins to two distinct intracellular domains of the delta opioid receptor. J Neurochem 2001; 76: 1887-1894. (Pubitemid 32221129)
28. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004; 27: 107-144. (Pubitemid 39050399)
29. Bradaia A, Berton F, Ferrari S, Luscher C. beta-Arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioids. Proc Natl Acad Sci USA 2005; 102: 3034-3039. (Pubitemid 40299911)
30. Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005; 5: 324-336. (Pubitemid 41486231)
31. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-273. (Pubitemid 41032989)
32. Bjork K, Rimondini R, Hansson AC, Terasmaa A, Hyytia P, Heilig M et al. Modulation of voluntary ethanol consumption by beta-arrestin 2. FASEB J 2008; 22: 2552-2560. (Pubitemid 351948672)
33. Sun D, Ma JZ, Payne TJ, Li MD. Beta-arrestins 1 and 2 are associated with nicotine dependence in European American smokers. Mol Psychiatry 2008; 13: 398-406. (Pubitemid 351399815)
34. Ikeda M, Ozaki N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y et al. Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes Brain Behav 2007; 6: 107-112. (Pubitemid 46090337)
35. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41: 563-572.
36. Walsky RL, Astuccio AV, Obach RS. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 2006; 46: 1426-1438. (Pubitemid 44704203)
37. Mannheimer B, Bahr CV, Pettersson H, Eliasson E. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Ther Drug Monit 2008; 30: 565-569.
38. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine h-1 receptor antagonists. Drug Metab Dispos 1998; 26: 536-539. (Pubitemid 28498358)
39. Division of Clinical Pharmacology, Indiana University. Cytochromes P450 drug-interaction table http://medicine.iupui.edu/clinpharm/ddis/table.asp.
40. Service de Pharmacologie et Toxicologie Cliniques, Hopitaux Universitaires de Geneve, Tables des interactions médicamenteuses et cytochromes P450 http://pharmacoclin.hug-ge.ch/-library/pdf/cytp450.pdf.
41. Zhang X, He JQ, Ding L, Pare PD, Sandford AJ. Promoter polymorphism and expression of beta-arrestin 2 in neutrophils. Clin Chim Acta 2007; 385: 79-80. (Pubitemid 47374673)
42. Liou YJ, Wang YC, Chen JY, Chen ML, Chen TT, Bai YM et al. The coding-synonymous polymorphism rs1045280 (Ser280Ser) in betaarrestin 2. (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia. Eur J Neurol 2008; 15: 1406-1408.
43. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229. (Pubitemid 34680308)
44. Boehringer S, Epplen JT, Krawczak M. Genetic association studies of bronchial asthma-a need for Bonferroni correction? Hum Genet 2000; 107: 197.
45. Buckland PR. Genetic association studies of alcoholism-problems with the candidate gene approach. Alcohol Alcohol 2001; 36: 99-103. (Pubitemid 32288306)
46. Bohn LM, Gainetdinov RR, Sotnikova TD, Medvedev IO, Lefkowitz RJ, Dykstra LA et al. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 2003; 23: 10265-10273. (Pubitemid 37444603)
47. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000; 408: 720-723. (Pubitemid 32015987)
48. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999; 286: 2495-2498.
49. Nielsen DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet 1998; 63: 1531-1540. (Pubitemid 30418550)
50. Wittke-Thompson JK, Pluzhnikov A, Cox NJ. Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 967-986. (Pubitemid 40705433)
51. Wang J, Shete S. A test for genetic association that incorporates information about deviation from Hardy-Weinberg proportions in cases. Am J Hum Genet 2008; 83: 53-63.
52. Jiang B, Shi Y, Li H, Kang L, Ma L. Decreased morphine analgesia in rat overexpressing beta-arrestin 2 at periaqueductal gray. Neurosci Lett 2006; 400: 150-153.